Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Atacand Advisory Cmte. To Focus On Concomitant Use With ACE Inhibitors

This article was originally published in The Pink Sheet Daily

Executive Summary

The focus of FDA's Cardiovascular & Renal Drugs Advisory Committee review of AstraZeneca's Atacand Feb. 24 will be narrowed to a discussion of concomitant use with angiotensin-converting enzyme inhibitors in treating congestive heart failure
Advertisement

Related Content

AstraZeneca's Atacand Heart Failure Indication Clears FDA Ahead Of Cmte. Review
AstraZeneca's Atacand Heart Failure Indication Clears FDA Ahead Of Cmte. Review
AstraZeneca's Atacand Heart Failure Indication Clears FDA Ahead Of Cmte. Review
AstraZeneca’s Atacand For Congestive Heart Failure To Receive FDA Cmte. Review

Topics

Advertisement
UsernamePublicRestriction

Register

PS061614

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel